Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome.

Abstract

Guillain-Barre syndrome is an acquired demyelinating polyneuropathy that is presumed to be immune-mediated. On the basis of this assumption, intravenous immunoglobulin (IVIG) has been used in the treatment of Guillain-Barre syndrome in recent years and found to be effective. To test this we performed a randomized study in patients with Guillain-Barre syndrome by giving IVIG (1 g/kg body weight per day over 2 consecutive days) in 9 children who were compared with 9 patients who were observed but not given specific therapy. We concluded that intravenous immunoglobulin is a safe and effective treatment for childhood Guillain-Barre syndrome which shortens the time to recovery.

• Authors: N Gürses, S Uysal, F Cetinkaya, I Işlek, A G Kalayci
• Journal: Scandinavian journal of infectious diseases (Scand J Infect Dis) Vol. 27 Issue 3 Pg. 241-3 ( 1995) ISSN: 0036-5548 [Print] England
• PMID: 8539548 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Immunoglobulins, Intravenous

Topics

• Adolescent
• Child
• Female
• Humans
• Immunoglobulins, Intravenous (therapeutic use)
• Male
• Polyradiculoneuropathy (physiopathology, therapy)
• Prognosis
• Respiration, Artificial